Last reviewed 2026-04-19 · How we verify

[212Pb]Pb-MP0712

Molecular Partners AG · Phase 1 active Small molecule

[212Pb]Pb-MP0712 is a Small molecule drug developed by Molecular Partners AG. It is currently in Phase 1 development. Also known as: [212Pb]Pb-DOTAM-MAM279.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	[212Pb]Pb-MP0712
Also known as	[212Pb]Pb-DOTAM-MAM279
Sponsor	Molecular Partners AG
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[212Pb]Pb-MP0712 CI brief — competitive landscape report
[212Pb]Pb-MP0712 updates RSS · CI watch RSS
Molecular Partners AG portfolio CI

Frequently asked questions about [212Pb]Pb-MP0712

What is [212Pb]Pb-MP0712?

[212Pb]Pb-MP0712 is a Small molecule drug developed by Molecular Partners AG.

Who makes [212Pb]Pb-MP0712?

[212Pb]Pb-MP0712 is developed by Molecular Partners AG (see full Molecular Partners AG pipeline at /company/molecular-partners-ag).

Is [212Pb]Pb-MP0712 also known as anything else?

[212Pb]Pb-MP0712 is also known as [212Pb]Pb-DOTAM-MAM279.

What development phase is [212Pb]Pb-MP0712 in?

[212Pb]Pb-MP0712 is in Phase 1.

Manufacturer: Molecular Partners AG — full pipeline
Also known as: [212Pb]Pb-DOTAM-MAM279

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing